Author

Christopher Gasink 1

1 Janssen Scientific Affairs, LLC,Horsham,United States of America

RESPONSE AND REMISSION AFTER 16 WEEKS OF USTEKINUMAB– AN ALL PATIENTS ANALYSIS FROM THE UNITI CROHN’S STUDIES

Jean-Frederic Colombel, Sheldon Sloan, Christopher Gasink, Long-Long Gao, Douglas Jacobstein, Scott D. Lee, Stephan Targan

ROLE OF CONCOMITANT IMMUNOSUPPRESSION IN THE EFFICACY AND SAFETY OF USTEKINUMAB: POST-HOC ANALYSES OF UNITI

Subrata Ghosh, Bernie Sattin, Douglas Jacobstein, L.L. Gao, Christopher Gasink, Paul Rutgeerts, Stephen B Hanauer

Safety of Ustekinumab in Inflammatory Bowel Diseases: Integrated Safety Analysis of Results from Phase 2 and 3 Studies in Crohn's Disease and Ulcerative Colitis

Subrata Ghosh, Bruce E. Sands, Christopher D. O'Brien, Ilia Tikhonov, Yiying Zhou, Sheri Volger, Colleen W. Marano, Elyssa Ott, Christopher Gasink, William Sandborn, Silvio Danese

USTEKINUMAB IMPROVES PRODUCTIVITY AND REDUCES WORK LIMITATION OF PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THREE PHASE 3 CLINICAL TRIALS

Bruce E. Sands, Chenglong Han, Dominik Naessens, Christopher Gasink, Douglas Jacobstein, L.L. Gao, Brian G. Feagan

USTEKINUMAB IV INDUCTION RESULTS IN CROHN’S DISEASE SYMPTOM IMPROVEMENT WITHIN THE FIRST WEEK IN ANTI-TNF REFRACTORY PATIENTS    

William Sandborn, Benjamin Yeager, Christopher Gasink, Timothy Hoops, Long-Long Gao, Yanli Wang, Douglas Jacobstein, Scott D. Lee, Stephen B Hanauer

Item 11 - 15 / 15
1
2